Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987435 | 0.84 | IMPDH2 (0.41) | HTR2AHTR2CHTR2BIMPDH2RPS6KA3 | |
| SCHEMBL13171270 | 0.80 | CDK4 (0.42) | HTR2AHTR2CHTR2BIMPDH2RPS6KA3 | |
| SCHEMBL13075204 | 0.76 | IMPDH2 (0.43) | HTR2AHTR2CHTR2BIMPDH2RPS6KA3 | |
| SCHEMBL29986726 | 0.75 | IMPDH2 (0.46) | HTR2AHTR2CHTR2BIMPDH2P4HB | |
| SCHEMBL2607319 | 0.74 | LMNA (0.53) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12045006 | 0.73 | LMNA (0.40) | HTR2AHTR2CHTR2BIMPDH2RPS6KA3 | |
| SCHEMBL31345172 | 0.73 | LMNA (0.40) | HTR2AHTR2CHTR2BIMPDH2RPS6KA3 | |
| SCHEMBL29959182 | 0.73 | LMNA (0.40) | HTR2AHTR2CHTR2BIMPDH2RPS6KA3 | |
| SCHEMBL19807266 | 0.73 | ALDH1A1 (0.44) | CYP1A2CYP2C9CYP2C19EIF4A3ALDH1A1 | |
| SCHEMBL21237350 | 0.73 | RPS6KA3 (0.44) | HTR2BRPS6KA3LMNALATS1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023086428-A2 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-10174017-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2018-08-02 | — | — | US | disclosed |
| US-8865709-B2 | Aminooxazole inhibitors of cyclin dependent kinases | Neosome Life Sciences, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140051694-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | Neosome Life Sciences, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8551992-B2 | Aminooxazole inhibitors of cyclin dependent kinases | Neosome Life Sciences, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8546400-B2 | 1,3-Oxazole-4-carboxamides, 1,3-Thiazole-4-carboxamides, and 1,3-Imidazole-d-carboxamides as Inhibitors of cyclin Dependent kinases | Neosome Life Sciences, LLC (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130184288-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | Neosome Life Sciences, LLC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120302578-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | Neosome Life Sciences, LLC (US) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184288-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | CDK1, CCNK, CCNI | HTR2A 3871/4885HTR2C 2786/4885HTR2B 3328/4885 |
| US-20120302578-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | CDK1, CCNK, CCNI | HTR2A 3871/4885HTR2C 2786/4885HTR2B 3328/4885 |
| US-20140051694-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | CDK1, CCNK, CCNI | HTR2A 3871/4885HTR2C 2786/4885HTR2B 3328/4885 |
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | HTR2A 336/4885HTR2C 477/4885HTR2B 534/4885 |
| US-10174017-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | HTR2A 336/4885HTR2C 477/4885HTR2B 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.